Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial.

Afsaneh AlaviErrol PrensAlexa B KimballJohn W FrewJames G KruegerSutirtha MukhopadhyayHeli GaoUsha RanganathanNathalie B IvanoffAna C Hernandez DalyChristos C Zouboulis

Published in: The British journal of dermatology (2024)

This exploratory proof-of-clinical-concept study supports the development of spesolimab as a new therapeutic option in HS. ClinicalTrials.gov identifier: NCT04762277.

Keyphrases

double blind
placebo controlled
clinical trial
hidradenitis suppurativa
phase ii
phase iii
study protocol
open label
phase ii study
squamous cell carcinoma
early onset
radiation therapy